

NLC Health Ventures

NLC HEALTH IMPACT FUND (IV)

Teaser

Your pathway to **high impact** and **high return** capital deployment in healthcare innovation



MANAGED BY A
CERTIFIED B
CORPORATION




ARTICLE NINE FUND
– DARK GREEN

SDG CONTRIBUTION



**Attention! This investment falls outside AFM supervision.
No license and no prospectus required for this activity.**



THE NLC HEALTH IMPACT FUND AT A GLANCE

Fund highlights



€100 million
Target fund size



> 80
Target no. investments



Seed and growth
Investment strategy



€15 million
Immediate deployment



10%
Max. single asset exposure



Europe and USA
Geographic focus



Value-added fund
Support from NLC platform



4 years
Investment period




10 + 1 + 1 years
Fund term

The initial close took place in June 2023 and since then the NLC Health Impact Fund has invested in 40 companies to date

Key data

Fund name	NLC Health Impact Fund Coöperatief U.A.
Fund jurisdiction	The Netherlands
Fund manager	NLC Fund Management B.V.
Fund type	Unlisted, closed-end fund
Minimum LP ticket	€5M (LPAC investors) €100K (non-voting investors)
Management fee	2% / 0.5% - effectively 1.1% over the lifetime
Carried interest	20% (above a 8% hurdle rate)
Investment per company	€150k – €5m per round, maximum exposure per asset capped at 10% of fund capital
Target IRR	25%

Fund composition



Venture capital

Co-invests 50% of growth capital in ventures that meet pre-defined thresholds

Discovery capital

Convertible loans at an early stage to secure a solid venture capital deal-flow

Seed portfolio

Instant deployment of €15m in a starting portfolio of 16 ventures



MEDTECH



DIGITAL HEALTH




BIOTECH



GREEN HEALTH

NLC HAS A PROVEN TRACKRECORD IN STRONG VALUE CREATION




THE FUND IS MANAGED BY EXPERIENCED PROFESSIONALS

Investment committee			Investment professionals	Operating Partner
 Peter Veldman <i>Chairman of the Investment Committee</i>	 Hidde ten Brink <i>Investment Director</i>	 Johanneke Maenhout <i>Portfolio Director</i>	 Nina Lameule  Jaap Haemers  Lars Olthof  Max Farrill  Jola Danaj  Kevin Ranner  Margarida Lopes	 > 70 highly skilled employees with in depth healthcare expertise Founded in 2015 NLC is the largest European healthtech venture builder. Since its inception, NLC has built over 120 ventures and set up four active funds to date.
<ul style="list-style-type: none"> ▶ Joined NLC in July 2023 ▶ 9 years of experience at EQT as managing director and deputy head of fund operations ▶ 7 years at Cyte Investment ▶ Over 12 years at ABN Amro and Delta Lloyd Asset Management 	<ul style="list-style-type: none"> ▶ Joined NLC five years ago ▶ Key role in all investment decisions ▶ Responsible for the team of investment professionals ▶ 14 years experience in Venture Capital, M&A and Corporate Finance 	<ul style="list-style-type: none"> ▶ Joined NLC over seven years ago ▶ Key role managing the Fund's portfolio and maximizing exit value ▶ In depth understanding of NLC's venture building process ▶ Over 16 years healthcare experience, including as Senior Manager at KPMG Healthcare 		

The NLC Health Impact Fund will optimally benefit from the vetting process by NLC, the Operating Partner

- ▶ The Operating Partner sources and analyses thousands of healthcare innovations each year and sets up companies based on only the most promising
- ▶ The NLC platform mitigates several idiosyncratic start-up risks (e.g. single person dependency, access to financing and (medical) specialists, etc.), substantially lowering the traditional risk curve
- ▶ The Fund invests in a selective number of ventures that have been vetted by the Operating Partner as well as financing providers



STRENGTHENED BY DEDICATED INVOLVEMENT BY CAPTAINS OF INDUSTRY IN PRIVATE INVESTING AND HEALTHTECH, AS WELL AS SPECIALISED PARTNERS



Rob ten Hoedt

Non-executive chairman of NLC
and captain of industry
healthtech



Peter Veldman

Chairman of IC HIF and captain
of industry fund management



Ivo Lurvink

Chairman of HIF LPAC and
captain of industry private
markets

Medtronic

Experience

- Executive Vice President and President Global Regions at Medtronic
- Vice-President and General Manager at Vitatron
- Vice-President Europe at Urologix

EQT OWNERSHIP CAPITAL Long-Horizon Investing **Cyrte** investments

Experience

- 9 years at EQT, the last 7 as Deputy Head of Fund Operations
- Managing Director at EQT
- COO at Ownership Capital
- COO at Cyrte Investments

CVC **ING**  **parcom** **PHILIPS**

Experience

- 7 years as Partner and Head of Amsterdam office at CVC
- Head of ING Group Investments
- Managing Director at Parcom Capital
- Business Group CEO, Head of Global M&A and Divisional CFO at Philips

Partners

FINNIUS
Legal and compliance

Confinant
AUDIT & ASSURANCE
Fund audit

IQEQ
Fund administration

THE HEALTH IMPACT FUND IS STRUCTURED TO CAPITALIZE ON THE SIGNIFICANT BENEFITS OF AN UPCOMING ASSET CLASS, THE VENTURE STUDIO MODEL

Research shows that ventures backed by large, specialised venture studio platforms, such as NLC, outperform standalone startups, due to:

Faster & more successful financing

Venture studio-founded startups not only **close seed rounds twice** as fast, but also progress through subsequent rounds 40% quicker. **84% of them secure seed rounds and 72% secure series A rounds**, compared to traditional startups with success rates of 42% for seed rounds and 60% for Series A rounds.

More frequent exits at higher valuations

Exit rates of venture studios are **2x the exit rate of VC funds** (16% vs 8%), take half as long (4y vs. 8y) and tend to achieve **1.5x higher exit valuations** (\$74M vs \$50M, on average).

Superior financial metrics

Investments by venture studios average a TVPI of 5.8 and IRR of 53%, which is **3.7x higher than the average TVPI and 2.5x higher than the average IRR** for traditional startup investments.

Significantly higher unicorn potential

Companies with three or four co-founders **become unicorns 78% more often**, while those with a single founder are 38% less likely.

More experienced leadership

Venture studios are able to establish 45-50-year-old professionals as co-founders, who have nearly **double the business success rate** of those who are 30 years old.

Source: "Big Startup Studios Research 2023" by Max Pog, published September 2023

Therefore, the NLC Health Impact Fund, which solely invests in NLC's portfolio, benefits from:



Improved financial performance



Increased investment efficiency



Lower risk of failure



Superior exit prospects

DISCLAIMER AND CONTACT DETAILS

Key considerations

- ▶ Please note that all investments carry (a degree of) risk. Prospective investors must take into account that the value of their investment could be lost, in full or in part. Unexpected developments can always occur that have a negative impact on the return development. This is also applicable to NLC and its funds.
- ▶ For an investment in the NLC Health Impact Fund specifically, prospective investors should be aware that some of the key risks of investing in this fund include:



Restricted
tradability



Start-up risk



Market risk

- ▶ These and other risks are explained in detail in the fund's information memorandum, which document should always be consulted by prospective investors before making an investment decision.

Contact details



Hidde ten Brink – Investment Director

Mobile: +31 6 36 10 35 66

Email: hidde.tenbrink@nlc.health



Johanneke Maenhout – Portfolio Director

Mobile: +31 6 41 31 43 40

Email: johanneke.maenhout@nlc.health



This document is a marketing statement and has been prepared by NLC Fund Management B.V. ('NLC') with the purpose of sharing relevant information concerning the NLC Health Impact Fund. It does not constitute an offer to sell or the solicitation of an offer to buy the securities described herein, which will only be made by means of an information memorandum and/or subscription documents. Please refer to the Information Memorandum and Key Information Document (EID) before making an investment decision. This document does not purport to be complete on any topic addressed. NLC has not verified or analyzed the information included in this document for accuracy or completeness. NLC shall not bear any liability for the information contained in, or any omissions from, this document.